Drug Database
Back to search

United Kingdom· GB-APID-37445311000001105

Libtayo 350mg/7ml concentrate for solution for infusion vials

A cemiplimab product containing cemiplimab, registered in United Kingdom by Regeneron UK Ltd. The same ATC class is registered in 12 of our 19 countries.

ATC L01FF06

Checked against NHS dm+d (United Kingdom) on

Informational only — not a medical device.

SOURCE REGISTER · GBNHS dm+d (United Kingdom)normalisedLibtayo 350mg/7ml concentrate for sol…ATCL01FF06REGISTER NO.GB-APID-3744531100000…PACKS LISTED3CHECKEDSeptember 13, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about cemiplimabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Cemiplimab is registered in 12 of 19 countries.

Countries holding a registration under ATC L01FF06 (cemiplimab), each read from that country’s own register.

  • This record: United Kingdom, from NHS dm+d (United Kingdom)
  • 8 of them publish a price we can compare per daily dose
Search cemiplimab products by name

Cemiplimab · ATC L01FF06

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

NHS dm+d (United Kingdom)
Active substance
Cemiplimab
Manufacturer
Regeneron UK Ltd
Country
United Kingdom (GB)
ATC code
L01FF06
ATC class
Cemiplimab
Defined daily dose
16.7 mg, P
Reimbursed
Not published by this register
Source register
NHS dm+d (United Kingdom)
Last checked
September 13, 2026

Packs & prices · 3

  • gtin
    5000283661320
  • gtin
    0361755008124
  • gtin
    00361755008254

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

17 interactions on record for cemiplimab.

Graded by severity as the source publishes them — 17 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check cemiplimab against other medicinesHow interaction checks work

Cemiplimab · interactions on record

17 records

  • 17 moderate

Most severe, free to view

  • PrednisoloneA07EA01moderate
  • HydrocortisoneA07EA02moderate
  • PrednisoneA07EA03moderate
  • BetamethasoneA07EA04moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Cemiplimab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All cemiplimab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Libtayo
  • Liechtenstein · Libtayo
  • Norway · Libtayo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/0910b961-f264-4c9a-b32b-1b27e4767a8a
GET /v1/drugs/0910b961-f264-4c9a-b32b-1b27e4767a8a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "apid": "37445311000001105",
  "desc": "Libtayo 350mg/7ml concentrate for solution for infusion vials (Regeneron UK Ltd)",
  "form": "Solution for infusion",
  "vpid": "37454311000001109",
  "source": "dmd",
  "vtm_id": "781612001",
  "strength": "50 mg",
  "substance": "Cemiplimab",
  "ingredient": "Cemiplimab",
  "supplier_code": "42368211000001107"
}
API referenceMCP serverPlans

See everything about cemiplimab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console